Loading market event…
Loading market event…
Worth noting Market event Mon, Nov 16 1 min read
Novo Nordisk released results from STEP Young, a phase 3 trial—the late stage of clinical testing that evaluates effectiveness and safety—of once-weekly Wegovy injections in children ages 6 to under 12 with obesity. The company said almost 80% of children receiving Wegovy reduced their body mass index, or BMI, by at least 10%, compared with 0% receiving placebo; BMI measures weight relative to height squared.[1]
Wegovy is already approved to treat obesity in children ages 12 and older, but the coverage says there are currently no approved obesity medicines for children under 12, so use in this younger group remains investigational.[2][1]
The efficacy results give Novo a stronger basis to seek approval for a younger age group. If regulators authorize that use, doctors could prescribe Wegovy to a new patient population, adding demand; the sales opportunity would also depend on acceptance by doctors and parents and on whether insurers or other payers cover treatment.[1][2]
Safety remains an important condition along that path. Related reporting says the study raised questions about children's growth rates, which could influence how regulators and doctors weigh the benefits of a lower BMI against developmental risks—and how quickly new demand materializes.[3]
Novo gains late-stage evidence supporting entry into a younger age group and gives rivals considering pediatric obesity treatments an efficacy benchmark. That strengthens the case for a broader potential market, but other medicines still need their own efficacy and safety evidence, while Wegovy's expansion depends on approval and resolution of growth-related questions.[1][2][3]